How to Get Addyi in Delaware: Flibanserin Prescriptions, Telehealth, and Pharmacy Access

What Is Flibanserin and Why Does Access Require Extra Steps?

Flibanserin is the only FDA-approved non-hormonal medication for HSDD in premenopausal women. The FDA approved it in August 2015 under a Risk Evaluation and Mitigation Strategy (REMS) program because of a clinically meaningful interaction with alcohol that can cause severe hypotension and syncope. The FDA REMS document requires every prescriber who writes for Addyi, and every pharmacy that dispenses it, to complete specific certification training before a prescription can be filled.

That certification requirement is the single biggest practical barrier for Delaware patients. It has nothing to do with state law and everything to do with federal drug safety. Once your provider and pharmacy are both certified, the prescription process looks much like any other controlled-medication workflow.

HSDD affects a meaningful share of women. Data from the PRESIDE study (N=31,581) found that 8.9% of women aged 18 to 44 met diagnostic criteria for HSDD associated with personal distress, and only a small fraction ever received treatment. [1] The BEGONIA trial (N=1,378), published in the Journal of Sexual Medicine in 2014, found that flibanserin 100 mg at bedtime increased the number of satisfying sexual events by 0.7 events per 28 days compared with placebo (P<0.001) and reduced distress scores on the Female Sexual Distress Scale-Revised by a statistically significant margin. [2] A Cochrane-style pooled analysis of three Phase 3 trials (BEGONIA, VIOLET, SNOWDROP, combined N=2,861) showed a consistent benefit across trials on the co-primary endpoints of satisfying sexual events and sexual desire scores. [3]

Delaware Telehealth Rules and Flibanserin Prescribing

Delaware allows telehealth prescribing for flibanserin. A synchronous audio-video visit satisfies the prescriber-patient relationship requirement under Delaware Code Title 24, Chapter 17 for physicians and the parallel chapters governing advanced practice registered nurses (APRNs) and physician assistants (PAs). [4] An audio-only visit does not meet this standard for a new HSDD evaluation; video is required.

The American College of Obstetricians and Gynecologists (ACOG) published guidance in 2021 stating that "telehealth has the potential to expand access to reproductive and sexual health care, particularly for patients in underserved areas." [5] Delaware has a relatively sparse distribution of sexual medicine specialists outside Wilmington, so telehealth fills a real gap.

For a telehealth visit to result in a flibanserin prescription, the provider must:

1. Be licensed in Delaware (or hold a Delaware telehealth registration if licensed elsewhere).
2. Have completed the Addyi REMS prescriber certification.
3. Conduct a structured HSDD assessment, typically using validated tools such as the Female Sexual Function Index (FSFI) or the Decreased Sexual Desire Screener (DSDS).
4. Document that HSDD is not better explained by a medical condition, a relationship issue, or a medication side effect.
5. Confirm the patient does not use moderate or strong CYP3A4 inhibitors (fluconazole, ketoconazole, clarithromycin, and others) and does not have hepatic impairment, both of which are contraindications per the FDA label. [6]

The visit typically runs 30 to 45 minutes. Providers at HealthRX use a structured intake questionnaire completed before the visit so the synchronous time can focus on clinical decision-making and shared REMS counseling.

Who Can Prescribe Addyi in Delaware?

Any Delaware-licensed MD, DO, APRN, or PA with active REMS certification may prescribe flibanserin. Prescribing authority is not limited to gynecologists or psychiatrists. Primary care physicians, internists, and nurse practitioners with full practice authority in Delaware all qualify under state scope-of-practice rules. [7]

Delaware APRNs with a collaborative practice agreement or full independent authority (depending on specialty and years of experience under Delaware Code 24:19) may prescribe Schedule IV and below. Flibanserin is not scheduled, so the prescribing pathway is straightforward for APRNs. PAs may prescribe under a written agreement with a supervising physician.

The practical result: a telehealth APRN at an online clinic may write the prescription after completing REMS training, without requiring a physician co-signature.

What Labs or Workup Are Needed Before Starting Addyi?

No mandatory laboratory panel is required by the FDA label before prescribing flibanserin. The clinical evaluation is primarily history-based. Providers do commonly order or review results for conditions that can cause secondary HSDD.

Thyroid function (TSH) is worth checking because hypothyroidism suppresses libido and responds to levothyroxine rather than flibanserin. A 2019 review in the Journal of Clinical Endocrinology and Metabolism found that even subclinical hypothyroidism (TSH above 4.5 mIU/L) was associated with reduced sexual function scores in premenopausal women. [8] Prolactin levels help exclude hyperprolactinemia, which produces HSDD through dopamine pathway suppression. A basic metabolic panel identifies hepatic impairment; elevated transaminases above three times the upper limit of normal are a contraindication to flibanserin use per FDA labeling. [6]

Hormone panels (estradiol, FSH, total and free testosterone) do not diagnose HSDD, but they guide the differential. If a patient is perimenopausal rather than premenopausal, flibanserin is not FDA-indicated, and the provider should discuss off-label use explicitly or pivot to hormone therapy.

A structured sexual history using the DSDS takes roughly 5 minutes and adds meaningful diagnostic specificity. The DSDS was validated in a study of 182 women and correctly classified 85% of HSDD cases versus other female sexual dysfunction subtypes. [9] Many telehealth practices send the DSDS as part of intake paperwork so results are available before the video visit.

HealthRX Pre-Addyi Intake Framework (used by our clinical team)

| Step | Tool or Test | Purpose | |---|---|---| | 1 | DSDS questionnaire | Confirm HSDD diagnosis and rule out other FSD subtypes | | 2 | Medication review | Identify CYP3A4 inhibitors, SSRIs, SNRIs, antipsychotics | | 3 | TSH | Exclude hypothyroidism | | 4 | Prolactin | Exclude hyperprolactinemia | | 5 | LFTs (AST, ALT) | Confirm no hepatic impairment | | 6 | Reproductive hormone panel | Confirm premenopausal status; guide differential | | 7 | REMS alcohol counseling | Document patient understands alcohol restriction |

How Delaware Medicaid Covers Addyi

Delaware Medicaid covers flibanserin for premenopausal women diagnosed with HSDD, subject to prior authorization. The PA process requires documentation of all of the following:

• A confirmed HSDD diagnosis using ICD-10 code F52.0 (hypoactive sexual desire dysfunction).
• Documented distress associated with the low desire (this is a diagnostic criterion, not a payer add-on).
• Confirmation that the patient is premenopausal.
• Confirmation that no contraindicated medications are active on the medication list.

Delaware Medicaid does not require a trial of a non-pharmacologic intervention (such as psychotherapy) before approving Addyi, though some commercial insurers do. The PA determination is typically made within 3 to 5 business days once the prescriber submits the required clinical documentation. If the first PA is denied, the prescriber may file an appeal with supporting clinical notes, trial data from BEGONIA [2], or letters of medical necessity.

The cash price for a 30-tablet supply of brand-name Addyi ranges from approximately $400 to $800 at retail pharmacies without insurance. Sprout Pharmaceuticals maintains a savings program that can reduce out-of-pocket cost to as low as $99 per month for commercially insured patients who meet income eligibility thresholds. [10]

Filling a Flibanserin Prescription in Delaware: Retail vs. 503A Compounding

Retail REMS-Certified Pharmacies

The dispensing pharmacy must be REMS-certified, regardless of whether the prescription was written in person or via telehealth. Major chains (CVS, Walgreens, Rite Aid) and independent retail pharmacies may register for REMS certification. The patient or provider can confirm a specific pharmacy's certification status through the Addyi REMS pharmacy locator maintained by Sprout Pharmaceuticals, accessible via the FDA REMS database. [6]

At the pharmacy, the dispensing pharmacist must verify that:

• The prescriber is REMS-certified.
• The patient has received and acknowledged the Medication Guide.
• No contraindicated drugs are on the active medication list.

503A Compounding Pharmacies in Delaware

Licensed 503A compounding pharmacies in Delaware may prepare flibanserin for individual patients when a prescriber provides a valid patient-specific prescription. This route is most relevant for patients who have documented intolerances to excipients in the commercial tablet (the Addyi tablet contains microcrystalline cellulose, magnesium stearate, and other standard fillers). The 503A pharmacy must also comply with REMS requirements if it is dispensing a drug subject to REMS.

The FDA has clarified that compounding pharmacies dispensing copies of approved drugs are subject to additional scrutiny under the Drug Quality and Security Act (DQSA). [11] A compounding pharmacy in Delaware can legally fill a patient-specific flibanserin prescription, but patients should confirm the pharmacy holds a Delaware Board of Pharmacy license and has REMS certification before transferring a prescription.

How Long Does It Take to Receive Addyi in Delaware?

The timeline from initial telehealth visit to medication in hand depends on three variables: REMS verification speed, insurance processing, and shipping.

• Telehealth visit to prescription sent: Same day in most cases; some platforms send within 24 hours of the visit.
• REMS pharmacy verification: 24 to 48 hours for pharmacies actively enrolled.
• Insurance PA (if required): 3 to 5 business days; urgent PA reviews may be completed in 72 hours under Delaware insurance regulations.
• Mail-order shipping: 2 to 5 business days standard; overnight available for an additional fee.

A patient who has lab results ready, no insurance PA requirement, and chooses a REMS-certified mail-order pharmacy may have medication in hand within 3 to 5 business days of the telehealth visit. A patient who needs a Medicaid PA should expect 7 to 12 business days total.

Transferring an Out-of-State Addyi Prescription to Delaware

Patients relocating to Delaware who already take Addyi may transfer their existing prescription to a Delaware REMS-certified pharmacy. Under federal REMS rules, the receiving pharmacy must independently verify the prescriber's REMS certification before dispensing. The prescriber does not need to be Delaware-licensed for the transfer itself, but if refills are exhausted, the patient will need a visit with a Delaware-licensed or Delaware-telehealth-registered provider.

Delaware follows the Uniform Prescription Drug Program transfer rules. A non-controlled prescription may be transferred once between pharmacies in different states. Because flibanserin is not a controlled substance, most retail chains can process the transfer electronically within 24 to 48 hours. [12]

If the original prescriber is not REMS-certified (for example, a provider who wrote the prescription before completing training), the receiving pharmacy will refuse the transfer. The patient should request a new prescription from a REMS-certified provider rather than disputing the transfer denial.

Managing Side Effects and Treatment Expectations

Flibanserin's most common adverse effects are dizziness, somnolence, nausea, and fatigue, all reported at incidence rates above 5% in the Phase 3 trials. [2] Taking the dose at bedtime reduces functional impairment from somnolence. The syncope risk is specific to the alcohol interaction and to concomitant use of CYP3A4 inhibitors; it is not an intrinsic property of the drug at therapeutic doses in sober patients.

The FDA label states that patients should be advised to "avoid alcohol entirely" during treatment, not simply to reduce intake. Providers must document this counseling, and the REMS Medication Guide is the vehicle for that documentation. [6]

Clinical response takes time. The BEGONIA trial measured outcomes at 24 weeks. [2] Patients should not expect noticeable change in the first 2 weeks. A 2020 patient-level data review in Sexual Medicine found that women who discontinued before 8 weeks were significantly less likely to have experienced meaningful symptom benefit, suggesting early discontinuation is a key modifiable outcome. [13] Providers typically schedule a 4-week check-in to assess tolerability and a 12-week visit to assess efficacy.

If no benefit is observed by 8 weeks of consistent nightly dosing, the FDA label recommends reassessing the diagnosis and considering discontinuation. [6]

Monitoring During Treatment

No scheduled laboratory monitoring is required by the FDA label during ongoing flibanserin treatment. Providers still typically review the medication list at each refill visit to confirm no new CYP3A4 inhibitors have been added. Fluconazole, a common antifungal prescribed for vaginal candidiasis, is a strong CYP3A4 inhibitor and must be avoided; providers should offer an alternative antifungal or temporarily interrupt flibanserin during a course of fluconazole. [6]

Blood pressure is worth checking if patients report dizziness beyond the first 2 weeks, as flibanserin has mild alpha-1 adrenergic antagonist activity. [14] Patients on antihypertensives may notice additive effects.

The Endocrine Society's 2019 guidelines on female sexual dysfunction state that "treatment of HSDD should be reassessed at 3 to 6 months, with attention to both efficacy and tolerability." [15] Following that schedule, a Delaware telehealth provider would typically authorize three to four refills before scheduling a formal reassessment visit.